SCHEMBL14633720

SCHEMBL14633720

Cc1ccc(Nc2ncc(-c3n[nH]c4c(F)c(F)ccc34)c(N)n2)cc1S(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 4/20 0.39
CDK1 P06493 3/20 0.39
LCK P06239 2/20 0.39
KDR P35968 2/20 0.39
STK17A Q9UEE5 2/20 0.39
CSNK2A1 P68400 2/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
PDPK1 O15530 1/20 0.39
DAPK3 O43293 1/20 0.39
JAK2 O60674 1/20 0.39
MAP4K4 O95819 1/20 0.39
PAK4 O96013 1/20 0.39
CHEK2 O96017 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
NTRK1 P04629 1/20 0.39
PRKCG P05129 1/20 0.39
INSR P06213 1/20 0.39
FYN P06241 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2468378 0.90 CDK1 (0.39) CDK2CDK1LCKKDRSTK17A
SCHEMBL14633954 0.89 JAK3 (0.42) CDK2CDK1LCKKDRSTK17A
SCHEMBL14634281 0.88 CDK1 (0.39) CDK2CDK1LCKKDRSTK17A
SCHEMBL2466308 0.86 GRM4 (0.41) CDK2CDK1LCKKDRSTK17A
SCHEMBL14634093 0.85 CDK2 (0.41) CDK2CDK1LCKJAK2SYK
SCHEMBL14633591 0.84 MEN1 (0.39) KDRFLT3JAK3ALKABCB11
SCHEMBL2472742 0.84 JAK2 (0.40) CDK2CDK1LCKKDRSTK17A
SCHEMBL2468759 0.83 NTRK1 (0.44) CDK2CDK1LCKKDRSTK17A
SCHEMBL14633971 0.83 SGK1 (0.39) CDK2CDK1LCKKDRSTK17A
SCHEMBL14634241 0.82 KDR (0.40) CDK1KDRCSNK2A1LYNFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 CDK2 22/4885CDK1 36/4885LCK 127/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 CDK2 1/4885CDK1 7/4885LCK 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.